fmp2.1

Vaccineexperimental

Clinical trial activity

5 trials · 11 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Nov 1, 2004 (NCT00349713)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • fmp2.1

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02044198Phase 1/Phase 2 (Phase 2)Mar 1, 2014Moorgreen Hospital, Southampton, National Institute for Health Research, United Kingdom, PATH, University of London, University of Oxford
NCT00460525Phase 2May 1, 2007GlaxoSmithKline, National Institute of Allergy and Infectious Diseases (NIAID), United States Army, University of Bamako, University of Maryland
NCT00358332Phase 1Nov 1, 2006GlaxoSmithKline, National Institute of Allergy and Infectious Diseases (NIAID), United States Army, University of Maryland
NCT00385047Phase 1/Phase 2 (Phase 2)Sep 1, 2006GlaxoSmithKline, PATH, United States Agency for International Development, United States Army
NCT00349713Phase 1Nov 1, 2004GlaxoSmithKline, National Institute of Allergy and Infectious Diseases (NIAID), United States Army, University of Bamako, University of Maryland
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (11)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
GlaxoSmithKlineFor profit4022004
United States ArmyGovernment4422004
National Institute of Allergy and Infectious Diseases (NIAID)Government3022004
University of MarylandAcademic/Hospital3022004
PATHAcademic/Hospital2012006
University of BamakoAcademic/Hospital2022004
Moorgreen Hospital, SouthamptonAcademic/Hospital1012014
National Institute for Health Research, United KingdomGovernment1012014
United States Agency for International DevelopmentGovernment1012006
University of LondonAcademic/Hospital1012014
University of OxfordAcademic/Hospital1112014
11 organizations
Page 1 / 1